OncoCyte Co. (NASDAQ:OCX) CFO Buys $200,000.05 in Stock

OncoCyte Co. (NASDAQ:OCX) CFO Andrea S. James purchased 97,561 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were acquired at an average cost of $2.05 per share, with a total value of $200,000.05. Following the completion of the transaction, the chief financial officer now owns 151,231 shares in the company, valued at $310,023.55. This trade represents a 181.78 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

OncoCyte Stock Up 14.5 %

Shares of OCX traded up $0.30 during mid-day trading on Tuesday, hitting $2.37. 362,186 shares of the company traded hands, compared to its average volume of 58,483. OncoCyte Co. has a 1 year low of $1.92 and a 1 year high of $3.48. The stock has a 50-day moving average price of $2.20 and a two-hundred day moving average price of $2.71.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.54). The company had revenue of $0.12 million during the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same period last year, the business earned ($0.57) EPS. Equities research analysts forecast that OncoCyte Co. will post -2.57 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OncoCyte stock. FNY Investment Advisers LLC grew its position in shares of OncoCyte Co. (NASDAQ:OCX) by 15.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 49,377 shares of the company’s stock after acquiring an additional 6,481 shares during the quarter. FNY Investment Advisers LLC owned about 0.29% of OncoCyte worth $117,000 at the end of the most recent reporting period. Institutional investors own 55.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on OCX. Needham & Company LLC reissued a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a report on Wednesday, November 13th. StockNews.com started coverage on OncoCyte in a research report on Monday, January 13th. They issued a “sell” rating on the stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.